Genmab: Daratumumab is becoming an increasingly critical asset for JNJ
BUY-Top Picks, Fair Value DKK1170 (+39%)
Ablynx: First bi-specific to reach the clinic in oncology
BUY, Fair Value EUR18 (+38%)
Ipsen: Botox approved in ALL in the US
BUY, Fair Value EUR63 (+17%)
SAP: FY15 conference call feedback: solid on revenues, but there is no free lunch
NEUTRAL, Fair Value EUR75 (+4%)
Delhaize: Q4 2015 trading statement (first take): so far so good
BUY, Fair Value EUR107 (+26%)
Cartagena Capital merges with Bryan, Garnier & Co
Combination with Northern European, Technology-Dedicated Corporate Finance Boutique Reinforces Bryan, Garnier & Co’s Position as the Leading European Investment Bank for Growth Companies.
Iliad: The wild child comes of age: thank you Orange!
BUY Coverage initiated, Fair Value EUR270 (+24%)
Software AG: Preliminary FY15 results above expectations, FY16 guidance exceeding hopes
BUY, Fair Value EUR33 (+28%)
Sanofi: Pre-Q4 results communication suggests caution
NEUTRAL, Fair Value EUR90 (+25%)